Publicaciones (142) Publicaciones de José Javier Aristu Mendioroz

2024

  1. First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies

    Clinical Genitourinary Cancer

2023

  1. Clinical feasibility of combining intraoperative electron radiation therapy with minimally invasive surgery: a potential for electron-FLASH clinical development

    Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 429-439

  2. Corrigendum: Practice-oriented solutions integrating intraoperative electron irradiation and personalized proton therapy for recurrent or unresectable cancers: Proof of concept and potential for dual FLASH effect, (Front. Oncol, (2022), 12, (1037262), 10.3389/fonc.2022.1037262)

    Frontiers in Oncology

  3. Hospital-based proton therapy implementation during the COVID pandemic: early clinical and research experience in a European academic institution

    Clinical and Translational Oncology, Vol. 25, Núm. 5, pp. 1268-1276

  4. Intraoperative Radiotherapy in Lung Cancer: Methodology (Electrons or Brachytherapy), Clinical Experiences, and Long-Term Institutional Results

    Medical Radiology (Springer Science and Business Media Deutschland GmbH), pp. 605-621

  5. Presence of Activated (Phosphorylated) STAT3 in Radiation Necrosis Following Stereotactic Radiosurgery for Brain Metastases

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  6. The addition of adjuvant radiotherapy in the management of extracranial arterio-venous malformations: A case discussion

    Journal of Radiotherapy in Practice, Vol. 22, Núm. 6

2022

  1. Intra-Operative Electron Radiation Therapy: An Update of the Evidence Collected in 40 Years to Search for Models for Electron-FLASH Studies

    Cancers, Vol. 14, Núm. 15

  2. Practice-oriented solutions integrating intraoperative electron irradiation and personalized proton therapy for recurrent or unresectable cancers: Proof of concept and potential for dual FLASH effect

    Frontiers in Oncology, Vol. 12

  3. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

2021

  1. Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 9

  2. Intraoperative electron beam radiotherapy and perioperative high-dose-rate brachytherapy in previously irradiated oligorecurrent gynecological cancer: clinical outcome analysis

    Clinical and Translational Oncology, Vol. 23, Núm. 9, pp. 1934-1941

2020

  1. ESTRO/ACROP IORT recommendations for intraoperative radiation therapy in primary locally advanced rectal cancer

    Clinical and Translational Radiation Oncology, Vol. 25, pp. 29-36

2019

  1. A novel concept to include uncertainties in the evaluation of stereotactic body radiation therapy after 4D dose accumulation using deformable image registration

    Medical Physics, Vol. 46, Núm. 10, pp. 4346-4355

  2. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Acta neuropathologica communications, Vol. 7, Núm. 1, pp. 64

  3. Erratum: Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience (PLoS ONE (2019)14:6 (e0217881)Doi:10.1371/journal.pone.0217881)

    PLoS ONE

  4. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience

    PLoS ONE, Vol. 14, Núm. 6

  5. Immune mechanisms mediating abscopal effects in radioimmunotherapy

    Pharmacology and Therapeutics, Vol. 196, pp. 195-203

  6. Long-term results of Perioperative High Dose Rate Brachytherapy (PHDRB) and external beam radiation in adult patients with soft tissue sarcomas of the extremities and the superficial trunk: Final results of a prospective controlled study

    Radiotherapy and Oncology, Vol. 135, pp. 91-99

  7. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1